Arbutus Biopharma Corporation (NASDAQ: ABUS), the biopharmaceutical company known for its focus on developing treatments for chronic Hepatitis B virus (HBV) infection, recently received a noteworthy boost in its stock price target. JMP Securities raised its price objective from $4.00 to $5.00,
AbbVie's financial performance and strategic initiatives in 2022 demonstrate a concerted effort to drive growth and enhance its presence in the pharmaceutical and biopharmaceutical sectors. With revenues exceeding $58 billion, the year reflected significant advancements fueled by new product
Sutro Biopharma, Inc., a clinical-stage oncology company, has garnered significant attention from the investment community. Institutional investors like Susquehanna Fundamental Investments LLC recently bolstered their holdings by acquiring 126,459 shares valued at approximately $714,000 during the
In a significant move within the pharmaceutical manufacturing industry, Veranova has announced a substantial $30 million investment to enhance its Devens, Massachusetts facility. This strategic expansion is designed to bolster Veranova’s capabilities in developing and manufacturing antibody-drug
In a move that reaffirms its position as a powerhouse in the life sciences sector, Merck has made a resounding statement with a substantial €180 million investment to expand its distribution center in Schnelldorf, Germany. This ambitious project has nearly doubled the existing facility's size by an
The biopharma industry stands at the crossroads of innovation and necessity as it leans into the burgeoning field of immunology. With the global immunology market anticipated to grow exponentially in the coming years, reaching numbers second only to oncology, major players and emerging startups
